Finance

Lists
WUXI06:BKK
Wuxi Biologics (Cayman) Inc. KKPS DR
5,20 ฿
0,00%
(0,00) 1D
15-окт., 16:40:00 GMT+7  ·   THB
All symbols
SymbolPriceChange% Change
Generating top insights for WUXI06...
Open
5,25 ฿
High
5,35 ฿
Low
5,05 ฿
Mkt. cap
198,43 млд
Avg. vol.
93,60 миң
Volume
288,50 миң
52-wk high
6,25 ฿
52-wk low
3,02 ฿
Shares outstanding
4,12 млд
No. of employees
15 миң
Open
5,25 ฿
High
5,35 ฿
Low
5,05 ฿
Mkt. cap
198,43 млд
Avg. vol.
93,60 миң
Volume
288,50 миң
52-wk high
6,25 ฿
52-wk low
3,02 ฿
Shares outstanding
4,12 млд
No. of employees
15 миң
News stories
From web sources and news partners
Profile
WuXi Biologics is a global Contract Research Development and Manufacturing Organization that provides open-access, integrated technology platforms for biologics drug development. WuXi Biologics' roots date back to 2010, when it was founded as a division of WuXi AppTec and began building out capabilities and facilities required for biologics discovery, development and good manufacturing practices. After being spun off from its parent, WuXi Biologics went public on the Hong Kong Stock Exchange in June 2017. As of 2021, WuXi Biologics has 18 manufacturing sites including ten in China, three in the United States, two in Ireland, two in Germany, and one in Singapore. In August 2020, WuXi Biologics was selected to become a component of the Hang Seng Index in Hong Kong. In January 2024, WuXi Biologics' share price fell on news that the United States Congress had introduced legislation to block any federal government contracts with the company due to national security concerns. The concerns stem from allegations, denied by the company, that it has worked closely with the People's Liberation Army as a part of the Chinese Communist Party's military-civil fusion strategy. Wikipedia
About Wuxi Biologics (Cayman) Inc. KKPS DR
CEOZhisheng Chen
Employees14,7 миң
Founded2010
Headquarters-
SectorHealth care
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
5,92 млд
5,92 млд
5,89 млд
5,89 млд
Cost of goods sold
3,04 млд
3,04 млд
3,17 млд
3,17 млд
Cost of revenue
3,04 млд
3,04 млд
3,17 млд
3,17 млд
Research and development expenses
254,93 млн
254,93 млн
215,11 млн
215,11 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
631,03 млн
631,03 млн
591,61 млн
591,61 млн
Operating expense
921,71 млн
921,71 млн
860,09 млн
860,09 млн
Total operating expenses
3,96 млд
3,96 млд
4,03 млд
4,03 млд
Operating income
1,96 млд
1,96 млд
1,86 млд
1,86 млд
Other non operating income
33,58 млн
33,58 млн
42,20 млн
42,20 млн
EBT including unusual items
1,96 млд
1,96 млд
1,71 млд
1,71 млд
EBT excluding unusual items
1,94 млд
1,94 млд
1,70 млд
1,70 млд
Income tax expense
476,10 млн
476,10 млн
251,54 млн
251,54 млн
Effective tax rate
24,24%
24,24%
14,71%
14,71%
Other operating expenses
-
-
-
-
Net income
1,28 млд
1,28 млд
1,22 млд
1,22 млд
Net profit margin
21,70%
21,70%
20,70%
20,70%
Earnings per share
-
-
-
-
Interest and investment income
115,29 млн
115,29 млн
106,38 млн
106,38 млн
Interest expense
-29,76 млн
-29,76 млн
-22,28 млн
-22,28 млн
Net interest expenses
85,53 млн
85,53 млн
84,10 млн
84,10 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
2,24 млд
2,24 млд
2,27 млд
2,27 млд
Gain or loss from assets sale
317,34 млн
317,34 млн
-
-
AI content may include mistakes. Learn more
Google колдонмолору